Editas Medicine (EDIT) Net Income towards Common Stockholders Growth (1y) (2016 - 2025)
Powered by 
Analysis
Editas Medicine (EDIT) Net Income towards Common Stockholders Growth (1y) (2016 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 59.58% |
| Jun 30, 2025 | 23.86% |
| Mar 31, 2025 | -22.12% |
| Dec 31, 2024 | -140.68% |
| Sep 30, 2024 | -38.02% |
| Jun 30, 2024 | -67.83% |
| Mar 31, 2024 | -30.57% |
| Dec 31, 2023 | 68.95% |
| Sep 30, 2023 | 19.22% |
| Jun 30, 2023 | 24.97% |
| Mar 31, 2023 | 5.63% |
| Dec 31, 2022 | -46.58% |
| Sep 30, 2022 | -42.52% |
| Jun 30, 2022 | 2.84% |
| Mar 31, 2022 | 11.40% |
| Dec 31, 2021 | 33.70% |
| Sep 30, 2021 | -600.08% |
| Jun 30, 2021 | -134.41% |
| Mar 31, 2021 | -50.43% |
| Dec 31, 2020 | -65.47% |